See more : MoneyOnMobile, Inc. (MOMT) Income Statement Analysis – Financial Results
Complete financial analysis of Mydecine Innovations Group Inc. (MYCOF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mydecine Innovations Group Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- BAVARIA Industries Group AG (B8A.DE) Income Statement Analysis – Financial Results
- Shanghai GenTech Co., Ltd. (688596.SS) Income Statement Analysis – Financial Results
- Artiva Biotherapeutics, Inc. Common Stock (ARTV) Income Statement Analysis – Financial Results
- Cettire Limited (CTTLF) Income Statement Analysis – Financial Results
- KESAR INDIA LIMITED (KESAR.BO) Income Statement Analysis – Financial Results
Mydecine Innovations Group Inc. (MYCOF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.mydecine.com
About Mydecine Innovations Group Inc.
Mydecine Innovations Group Inc., a biotech and life sciences company, engages in the development and commercialization of drugs for treating mental health problems. It develops therapies for veterans, emergency medical service providers, post-traumatic stress disorder, and front-line workers; and operates Mindleap, a digital telehealth platform that provides access to mental health services, as well as psychedelic integration services, including psychedelic aftercare and wellness services. The company also engages in the drug discovery and builds nature-sourced psychedelic-assisted therapeutics, compounds, therapy protocols, and unique delivery systems. In addition, it operates hemp farm in Pottus, Texas. Mydecine Innovations Group Inc. has a partnership with Leiden University Medical Center; Royal Ottawa Mental Health Centre; LeadGen Labs to support psychedelic drug development; and Applied Pharmaceutical Innovation for drug development and clinical trial programs. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 7.49K | 58.49K | 125.57K | 207.66K | 0.00 | 0.00 | 84.00K | 84.00K | 49.00K | 0.00 |
| Cost of Revenue | 9.88K | 128.86K | 0.00 | 37.37K | 94.05K | 109.82K | 246.58K | 1.77M | 1.97M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -9.88K | -128.86K | 7.49K | 21.12K | 31.52K | 97.83K | -246.58K | -1.77M | -1.88M | 84.00K | 49.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 36.11% | 25.10% | 47.11% | 0.00% | 0.00% | -2,243.43% | 100.00% | 100.00% | 0.00% |
| Research & Development | 1.08M | 3.59M | 3.96M | 1.29M | 0.00 | 0.00 | 0.00 | 0.00 | 1.05K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 7.15M | 9.98M | 14.74M | 7.74M | 3.27M | 4.88M | 14.62M | 3.92M | 3.64M | 808.13K | 46.40K | 0.00 |
| Selling & Marketing | 1.15M | 0.00 | 0.00 | 2.33M | 71.51K | 730.22K | 693.83K | 259.75K | 41.10K | 14.00K | 0.00 | 0.00 |
| SG&A | 8.30M | 9.98M | 14.74M | 10.07M | 3.34M | 5.61M | 15.31M | 4.18M | 3.68M | 822.13K | 46.40K | 12.97 |
| Other Expenses | 0.00 | 2.82M | 3.99M | 292.02K | 149.99K | -4.54M | -97.92K | -4.28K | -2.95K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 19.64M | 16.39M | 22.69M | 11.65M | 3.49M | 5.90M | 15.70M | 4.19M | 3.81M | 929.46K | 73.26K | 41.06 |
| Cost & Expenses | 19.64M | 16.39M | 22.69M | 11.69M | 3.58M | 6.01M | 15.70M | 4.19M | 3.81M | 929.46K | 73.26K | 41.06 |
| Interest Income | 0.00 | 911.59 | 205.27 | 24.67 | 0.00 | 18.62K | 0.00 | 0.00 | 75.00 | 7.00 | 102.00 | 44.97 |
| Interest Expense | 1.30M | 911.59K | 205.27K | 182.87K | 68.31K | 69.95K | 6.90K | 47.42K | 107.13K | 30.02K | 32.88K | 0.00 |
| Depreciation & Amortization | 9.88K | 128.86K | 235.18K | 57.08K | 46.39K | 21.76K | 246.58K | 9.00K | 24.56K | 25.05K | 25.70K | 26.58 |
| EBITDA | -9.38M | -15.92M | -23.14M | -11.12M | -3.21M | -5.78M | -15.46M | -4.18M | -3.83M | -1.17M | 1.44K | -14.21 |
| EBITDA Ratio | 0.00% | 0.00% | -304,709.21% | -19,007.40% | -2,555.37% | -2,782.25% | 0.00% | 0.00% | -4,582.18% | -976.67% | 3.14% | 0.00% |
| Operating Income | -9.39M | -16.05M | -23.07M | -11.21M | -3.32M | -5.80M | -15.70M | 4.19M | 3.72M | 1.11M | 24.16K | -40.80 |
| Operating Income Ratio | 0.00% | 0.00% | -307,847.83% | -19,161.62% | -2,642.24% | -2,792.73% | 0.00% | 0.00% | 4,430.54% | 1,320.65% | 49.31% | 0.00% |
| Total Other Income/Expenses | -11.55M | -1.40M | -515.87K | -15.67M | -18.04M | -7.55M | -1.99M | -3.79M | -264.53K | -464.40K | -83.34K | -45.24 |
| Income Before Tax | -20.95M | -17.24M | -23.58M | -26.95M | -3.51M | -13.36M | -17.56M | -7.96M | -4.64M | -1.23M | -107.60K | -86.03 |
| Income Before Tax Ratio | 0.00% | 0.00% | -314,732.56% | -46,074.45% | -2,793.41% | -6,431.45% | 0.00% | 0.00% | -5,524.04% | -1,458.97% | -219.59% | 0.00% |
| Income Tax Expense | 0.00 | -5.39M | 5.14M | 608.14K | 219.51K | 69.95K | 6.90K | -306.19K | 107.13K | 30.02K | 32.88K | 0.00 |
| Net Income | -20.95M | -11.85M | -28.72M | -27.56M | -3.73M | -13.36M | -17.56M | -7.60M | -4.64M | -1.23M | -107.60K | -86.03 |
| Net Income Ratio | 0.00% | 0.00% | -383,287.92% | -47,114.19% | -2,968.22% | -6,431.45% | 0.00% | 0.00% | -5,524.04% | -1,458.97% | -219.59% | 0.00% |
| EPS | -0.68 | -1.37 | -6.13 | -12.12 | -8.37 | -122.07 | -311.45 | -243.37 | -191.20 | -58.15 | -44.08 | 0.00 |
| EPS Diluted | -0.68 | -1.37 | -6.13 | -12.12 | -8.37 | -122.07 | -311.15 | -243.37 | -191.20 | -58.15 | -44.08 | 0.00 |
| Weighted Avg Shares Out | 30.70M | 8.65M | 4.68M | 2.27M | 445.47K | 109.41K | 56.37K | 31.25K | 24.27K | 21.08K | 2.44K | 0.00 |
| Weighted Avg Shares Out (Dil) | 30.70M | 8.65M | 4.68M | 2.27M | 445.47K | 109.41K | 56.43K | 31.25K | 24.27K | 21.08K | 2.44K | 0.00 |
Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds
Mydecine Innovations Group Announces Director Resignation
Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound
Mydecine Announces Update Regarding the Special Access Program
Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements
Mydecine Provides Q4 2023 Business Update
Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO
Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date
Mydecine Innovations Announces Amended Press Release Relating to the Closing of Prospectus Supplement Financing
Mydecine Innovations Announces Closing of Prospectus Supplement Financing
Source: https://incomestatements.info
Category: Stock Reports